Traws Pharma (NASDAQ:TRAW) reported quarterly earnings of $2.09 per share which beat the analyst consensus estimate of $(8.04) by 126 percent. This is a 135.3 percent increase over losses of $(5.92) per share from the same period last year. The company reported quarterly sales of $57.00 thousand which missed the analyst consensus estimate of $60.00 thousand by 5.00 percent. This is a 1.79 percent increase over sales of $56.00 thousand the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。